MedImmune works to boost the immune systems of babies and grown-ups. Its flagship biotech product, Synagis, prevents respiratory syncytial virus (RSV), a major cause of pneumonia and other respiratory disease in infants and children. Also on the market are FluMist, its nasal spray flu vaccine, and Ethyol (amifostine), which treats side effects of chemotherapy and radiation. The company is working on dozens of investigational therapies -- including monoclonal antibodies, vaccines, and small molecule drugs -- in the areas of infectious disease, cancer, inflammation, and autoimmune and respiratory conditions. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca.